Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 6OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × fluoromisonidazole × Clear all
NCT00544674 2012-12-10

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Proacta, Incorporated

Phase 2 Terminated
5 enrolled 7 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡